SCHEMBL5423474

SCHEMBL5423474

CCN(CC)C(=O)c1ccc(CCCCCCC#N)nc1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 4/20 0.43
GRM5 P41594 1/20 0.42
ALDH1A1 P00352 5/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 4/20 0.38
MAPT P10636 2/20 0.38
ATM Q13315 1/20 0.37
HSP90AA1 P07900 3/20 0.36
HSP90AB1 P08238 3/20 0.36
LMNA P02545 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5434700 0.85 RARB (0.47) GRM5ALDH1A1NPC1HPGDMAPT
SCHEMBL12844304 0.76 GRM5 (0.52) MLYCDGRM5ALDH1A1L3MBTL1NPC1
SCHEMBL29133579 0.75 GRM5 (0.51) MLYCDGRM5ALDH1A1L3MBTL1NPC1
SCHEMBL5437061 0.73 GRM5 (0.47) MLYCDGRM5ALDH1A1L3MBTL1NPC1
SCHEMBL2961669 0.73 GRM5 (0.49) MLYCDGRM5ALDH1A1L3MBTL1NPC1
SCHEMBL5909282 0.71 GAA (0.47) GRM5HPGDLMNAHRH3
SCHEMBL12844312 0.70 ALDH1A1 (0.44) MLYCDALDH1A1L3MBTL1NPC1HPGD
SCHEMBL11332811 0.70 HPGD (0.43) MLYCDGRM5ALDH1A1L3MBTL1HPGD
SCHEMBL5430899 0.69 HCAR3 (0.54) MLYCDGRM5ALDH1A1L3MBTL1NPC1
Hydrochloric Acid SCHEMBL11329758 0.69 HPGD (0.43) MLYCDGRM5ALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 MLYCD 2355/4885GRM5 2316/4885ALDH1A1 837/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 MLYCD 2355/4885GRM5 2316/4885ALDH1A1 837/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 MLYCD 2738/4885GRM5 2896/4885ALDH1A1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.